B
086040
vs
K
KOSPI 200
Over the past 12 months, Biotoxtech Co Ltd has underperformed KOSPI 200, delivering a return of +15% compared to the KOSPI 200's +117% growth.
Stocks Performance
086040 vs KOSPI 200
Performance Gap
086040 vs KOSPI 200
Performance By Year
086040 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Biotoxtech Co Ltd
Glance View
Biotoxtech Co., Ltd. engages in the provision of non-clinical drug trials. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2007-09-21. The firm provides safety evaluation research, efficacy evaluation research and analysis research. Its safety evaluation research business provides general toxicity tests, local toxicity tests, reproductive and development tests, genotoxicity tests, immunotoxicity tests, carcinogenicity tests, safety pharmacology tests, ecotoxicology tests, histopathology tests and hematology tests. Its efficacy evaluation research business provides efficacy evaluation of medical supplies, health supplements and cosmetics. Its analysis research business provides pharmacokinetics (PK) tests and toxicokinetics (TK) tests services, as well as validation and bio analysis services. On March 13, 2013, the Company acquired a 60% stake in its new established subsidiary.
